Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations

[1]  H. Döhner,et al.  Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. , 2016, Blood.

[2]  T. Shanafelt,et al.  Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. , 2016, Blood.

[3]  R. Rabadán,et al.  Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia , 2016, Haematologica.

[4]  A. López-Guillermo,et al.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.

[5]  M. Negrini,et al.  Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations , 2015, Genes, chromosomes & cancer.

[6]  A. Pettitt,et al.  Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. , 2015, Blood.

[7]  F. Stingo,et al.  Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens , 2015, Cancer.

[8]  R. Foà,et al.  Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. , 2015, Blood.

[9]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[10]  Catherine J. Wu,et al.  Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. , 2015, Blood.

[11]  M. Odenthal,et al.  Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing , 2015, PloS one.

[12]  Viktor Ljungström,et al.  Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting , 2015, Haematologica.

[13]  Š. Pospíšilová,et al.  Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia , 2014, Leukemia.

[14]  H. Döhner,et al.  Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. , 2014, Blood.

[15]  E. Campo,et al.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.

[16]  T. Shanafelt,et al.  CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Negrini,et al.  Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups , 2014, Cancer medicine.

[18]  Marilyn M. Li,et al.  Clinical application of amplicon-based next-generation sequencing in cancer. , 2013, Cancer genetics.

[19]  Raul Rabadan,et al.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.

[20]  M. Ferracin,et al.  Genetic subclonal complexity and miR125a-5p down-regulatio identify a subset of patients with inferior outcome in low-ris CLL patients , 2013, Oncotarget.

[21]  Michael Hallek,et al.  Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment , 2013, American journal of hematology.

[22]  D. Catovsky,et al.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.

[23]  M. Cazzola,et al.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.

[24]  M. Cazzola,et al.  NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. , 2012, Blood.

[25]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[26]  J. Gribben,et al.  ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia , 2012, Leukemia.

[27]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[28]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[29]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[30]  L. Pasqualucci,et al.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.

[31]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[32]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[33]  A. Cuneo,et al.  Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in Splenic Marginal Zone Lymphoma , 2011, Journal of biomedicine & biotechnology.

[34]  Marcos González,et al.  Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis , 2008, British journal of haematology.

[35]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[36]  John C Reed,et al.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Veronese,et al.  Chronic lymphocytic leukemia with 6q− shows distinct hematological features and intermediate prognosis , 2004, Leukemia.

[38]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[39]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[40]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[41]  D. Catovsky,et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.

[42]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.

[43]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[44]  An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. , 2016, The Lancet. Oncology.

[45]  A. Kohlmann,et al.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients , 2014, Leukemia.

[46]  R. Dalla‐Favera,et al.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.

[47]  M. Negrini,et al.  Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. , 2012, Blood.

[48]  H. Döhner,et al.  From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.

[49]  T. Haferlach,et al.  The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.